Liquidia Corporation
LQDA Healthcare Drug Manufacturers Specialty & Generic
Liquidia Corporation’s revenue for fiscal 2025 (year ended December 2025) was $158.3 million, up 1,031.2% from fiscal 2024. In the quarter to June 2026, revenue grew 1,842.7%, EPS grew 271.4%, free cash flow grew 270.2% and total debt fell 9.04%, each against the same quarter a year earlier.
Follow LQDA
Liquidia Corporation (LQDA) EV/Sales
As of 16 October 2026, Liquidia Corporation (LQDA) trades at a EV/Sales of 6.5×. Over the past ten years it has ranged from 1.9× (July 2018) to 130× (September 2025); the current reading is higher than 18% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 18.8× | (69.57%) |
| FY2024 | 61.6× | 51.40% |
| FY2023 | 40.7× | 116.83% |
| FY2022 | 18.8× | 15.04% |
| FY2022 | 16.3× | 6.83% |
| FY2021 | 15.3× | 186.72% |
| FY2021 | 5.3× | 3.34% |
| FY2020 | 5.2× | 19.61% |
| FY2020 | 4.3× | 5.51% |
| FY2019 | 4.1× | (90.59%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 15.5× | 36.08% |
| Mar 2026 | 11.4× | (39.35%) |
| Dec 2025 | 18.8× | (35.05%) |
| Sep 2025 | 28.9× | (48.66%) |
| 25 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | −0.1× |
| PRGO Perrigo Company plc compare | 1.3× |
| BCRX BioCryst Pharmaceuticals, Inc. compare | 2.6× |
| SUPN Supernus Pharmaceuticals, Inc. compare | 2.8× |
| INDV Indivior Pharmaceuticals Inc. compare | 3.1× |
| PBH Prestige Consumer Healthcare Inc. compare | 3.9× |
| LQDA Liquidia Corporation | 6.5× |
| ALVO Alvotech compare | 9.0× |
| AMLX Amylyx Pharmaceuticals, Inc. compare | 30.7× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)